Soligenix Inc (SNGX)

[236T568]

See bold red below


http://ih.advfn.com/p.php?pid=nmona&article=73941765&symbol=SNGX

Item 7.01 Regulation FD Disclosure.

Soligenix, Inc. (the “Company”) has updated its corporate presentation (the “Presentation”) as of February 23, 2017. Consistent with the Company’s previously disclosed business strategy to allocate funds to completing the pivotal Phase 3 clinical trial of SGX301 for the treatment of cutaneous T-cell lymphoma and to initiating the pivotal Phase 3 protocol of SGX942 for the treatment of oral mucositis in head and neck cancer patients, the Presentation reflects the revised estimated schedule for the Company’s Phase 3 clinical program for SGX203 for the treatment of pediatric Crohn’s disease, which is expected to commence during the second half of 2017 with results anticipated during the second half of 2019.

The Presentation also was updated to reflect the amount of funding the Company has received to date under government contracts from the Biomedical Advanced Research and Development Authority (“BARDA”) and the National Institute of Allergy and Infectious Diseases for the advanced preclinical and manufacturing development of OrbeShield ® for the treatment of gastrointestinal acute radiation syndrome, as a result of BARDA electing not to extend the current contract. The Company’s biodefense programs will continue to be supported by the contract with the National Institutes of Health (the “NIH”) for the development of RiVax ™ to protect against exposure to ricin toxin that would provide up to $24.7 million of funding in the aggregate if options to extend the contract are exercised by the NIH. The Company plans to continue applying for additional non-dilutive government funding for its biotherapeutics and vaccines/biodefense programs through grants and contracts.

The slides from the Presentation are attached hereto as Exhibit 99.1. The attached materials will be posted on the Company’s website at www.soligenix.com. The Company does not undertake to update this Presentation.